Stifel analyst Annabel Samimy started Evolus (EOLS) with a Buy rating and $27 price target, citing her view of the potential for Jeuveau to be an identical, drop-in, “frictionless” replacement for Allergan’s (AGN) Botox with “a marketing angle and pedigree that no other toxin has claimed before.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.